NewAmsterdam Pharma

Cardiovascular disease is the leading cause of death in the Western world, and hypercholesterolemia is one of the most significant modifiable risk factors. Statins revolutionized prevention over the past decades, but not all patients respond adequately, and not all can tolerate the side effects. NewAmsterdam Pharma was born precisely at the intersection of this unmet medical need and the possibility of developing new molecules that act on mechanisms different from those targeted by statins. The biopharmaceutical company, headquartered in Naarden in the Netherlands, focuses on innovative therapies for hypercholesterolemia and cardiometabolic diseases, with an advanced pipeline of small molecule candidates in late-stage development. Founded by Michael Davidson, NewAmsterdam distinguishes itself through the scientific rigor of its pipeline and its choice to pursue robust clinical development pathways before seeking commercial partners or pursuing a public listing. The business model is based on drug research and development followed by licensing to pharmaceutical partners — an approach that maximizes the value of intellectual property before commercial rights are transferred. In a market where cardiovascular drugs generate tens of billions annually and where demand for alternatives to existing therapies is structural, NewAmsterdam Pharma's positioning is strategically sound. The challenge is the one every late-stage biotech faces: moving molecules through clinical trials and demonstrating not just efficacy but a superior safety profile compared to what is already available.